Researchers developed a novel compound that stops cancer cells from invading healthy brain tissue, improving treatment outcomes in animal models. The compound, imipramine blue, is combined with chemotherapy to enhance its effectiveness.
Researchers at the University of Alberta discovered that some breast cancer tumors with weak 'survival' systems responded better to taxane chemotherapy than those with strong survival systems. This finding could lead to new strategies for identifying patients who may not respond to this common treatment.
Researchers aim to create targeted compounds that selectively attack cancerous cells by zeroing-in on pollutants produced by tumors' characteristic metabolism. This approach seeks to minimize side effects associated with conventional chemotherapy.
Researchers found a strong correlation between genetic variation and chemotherapy side effects, enabling personalized treatment approaches. This study aims to tailor chemotherapy regimens to individual patients' genetic profiles.
A new genomic test has been shown to help doctors identify breast cancer patients who do not need adjuvant chemotherapy, reducing side effects and improving quality of life. The study found that patients classified as low risk by the test had a higher distant disease-free survival rate compared to those classified as high risk.
A recent study found that Asian breast cancer patients suffer from memory loss, decision-making difficulties, and speech problems after chemotherapy treatment. To cope with these changes, many turned to mind stimulation activities such as mahjong and qi gong.
Breast cancer in pregnant women is common and treatable with surgery or chemotherapy. A normal-length pregnancy should be the aim to avoid premature birth. Chemotherapy can be given as per standard guidelines, but radiation therapy is not advised due to fetal shielding concerns.
A new study found that short fasting cycles can work as well as chemotherapy to treat cancer in mice, and combining both greatly improves survival rates. Fasting alone also effectively treated a majority of cancers tested in animals, including those from human cells.
Advanced head and neck cancer patients treated with radiation plus chemotherapy showed improved local-regional control and disease-free survival rates compared to those treated with radiation alone. At 10 years post-treatment, the local-regional failure rates were lower for those who received both therapies.
A study published in Leukemia identifies a molecular braking process that acute myeloid leukemia (AML) cells use to evade chemotherapy, allowing them to survive treatment. When this brake is removed, AML cells die, providing hope for improved survival rates for patients with the disease.
Researchers found that chemotherapy can lead to DNA damage in cancer cells, which can cause them to evolve and become resistant to treatment. The study suggests that targeted therapies based on individual mutations may be more effective than current treatments.
Researchers have discovered a way to selectively target the glutathione pathway in brain cancer cells, making them more susceptible to chemotherapy. The breakthrough could potentially improve treatment outcomes for the nearly 45,000 people diagnosed with brain cancer each year.
A systematic review and meta-analysis of randomized control trials found no improvement in overall survival for adult patients with advanced follicular lymphoma who received high-dose chemotherapy and ASCT compared to conventional-dose chemotherapy alone. The study concluded that HDC-ASCT is not effective as a primary treatment option.
A new analysis found that breast cancer survivors may experience mental abilities problems several years after treatment, regardless of therapy type. Chemotherapy was linked to persistent cognitive issues, while radiation also caused similar problems in some cases.
A standard chemotherapy regimen has been shown to increase survival rates in patients with limited-stage Hodgkin's lymphoma. This finding is significant, as it may lead to reduced radiation exposure and lower risk of long-term complications.
A significant number of women with breast cancer are not receiving guideline-recommended adjuvant treatment. The research found that socioeconomic factors such as poverty, insurance status, and education level significantly contribute to this disparity. Women from high-poverty areas were less likely to receive guideline therapy, highli...
A new triple drug combination has been shown to increase tumour eradication in HER2-positive breast cancer by more than half, with 46% of patients achieving a pathological complete response. The treatment was well-tolerated and did not significantly increase side effects or cardiac risk compared to standard therapy.
A follow-up study by Moffitt Cancer Center researchers found that patients who received chemotherapy for breast cancer may experience prolonged fatigue years after treatment. This contradicts prior research and has important implications for patient education and fatigue monitoring during follow-up.
A meta-analysis of 123 randomised trials involving 100,000 women with breast cancer shows that modern chemotherapy regimens reduce breast cancer mortality by around one-third compared to no chemotherapy. The findings suggest that standard 1980s chemotherapy regimens could produce a reduction of almost a quarter in breast cancer mortality.
A UK study published in The Lancet found that a surveillance-only policy can be effective for women with high human chorionic gonadotropin (hCG) concentrations after molar pregnancies. Nearly all patients will spontaneously remit, avoiding unnecessary chemotherapy and its side effects.
A new study reveals that more intensive chemotherapy regimens significantly improve event-free survival and reduce mortality in younger patients with aggressive diffuse large B-cell lymphoma. Younger patients who received dose-intensive chemotherapy had an 81% event-free survival rate, compared to 67% for those on standard treatment.
A study published in Archives of Neurology found that breast cancer survivors who received chemotherapy demonstrated reduced activation in key brain areas and poorer executive function. The researchers also discovered that negative effects of chemotherapy may be exacerbated by factors such as age and educational level.
Scientists at Dana-Farber Cancer Institute have developed a test that can predict how effective chemotherapy agents will be against a patient's tumor cells. By measuring the proximity of cancer cells to self-destruction, researchers found that tumors with higher mitochondrial priming are more susceptible to chemotherapy.
A phase 2 trial shows that combining standard chemotherapy with a new cancer vaccine enhances treatment effect and slows disease progression in NSCLC patients. The vaccine stimulates an immune response against the MUC1 protein, which is overexpressed in 60% of NSCLCs.
G-Zero Therapeutics, a UNC spin-off, has received a $3 million Small Business Innovation Research Grant to commercialize technology protecting patients from cellular damage caused by radiation or cancer chemotherapy. The grant will fund the development of treatments for bone marrow toxicity resulting from radiation and chemotherapy.
Researchers tested a combination of oral drug sorafenib and microbead chemotherapy directly into tumors in advanced liver cancer patients. The treatment showed promise with no increased side effects compared to existing therapies.
A study found that children born after mothers received chemotherapy during pregnancy had normal cognitive and cardiac development, but those born preterm were more likely to experience developmental delays. Researchers recommend continuing cancer treatment during pregnancy unless preterm delivery can be prevented.
A major UK trial found that giving radiotherapy between or during chemotherapy cycles significantly reduces the risk of breast cancer recurring in the breast or chest wall. The treatment, known as synchronous chemoradiation, has minimal adverse side-effects and no detrimental effect on quality of life.
Researchers at Moffitt Cancer Center have identified a molecular pathway that may play a key role in the evolution of chemotherapy resistance in ovarian cancer. The 'BCL2 antagonist of cell death' (BAD) pathway shows promise as a biomarker to identify patients with high-risk ovarian cancer and potentially reverse chemo-resistance.
Researchers have successfully delivered chemotherapy to cancer cells inside tiny microparticles, reducing ovarian cancer tumours by 65 times more than traditional methods. The 'Trojan Horse' approach uses a special protein called CD95 to hijack cancer cells and deliver the chemotherapy cargo.
Researchers at University Medical Center Utrecht discovered that fish oil supplements containing omega-3 and omega-6 fatty acids can induce resistance to a broad spectrum of chemotherapies. The study found that the body's own protective substances, which are also present in fish oil, can block the effect of chemotherapy.
Research from the University of Gothenburg found that chemotherapy can cause significant language difficulties in cancer patients, including trouble with sentence completion and word order. The study used a unique questionnaire to assess everyday life difficulties, resulting in an 80% response rate and a long follow-up period.
A new study found that MRI-assessed tumor responses to neoadjuvant therapy can predict survival among patients with advanced rectal cancer. The findings suggest that using MRI prior to surgery may help change the course of patient care, enabling physicians to choose a more effective chemotherapy drug or avoid surgery in some cases.
A recent UCSF study analyzes the long-term effects of chemotherapy on women's reproductive health, finding that younger women are more likely to experience early menopause and infertility. The research provides new insights for patients and clinicians, enabling more strategic and personalized counseling about fertility preservation.
A U-M study found that nearly 17% of oncology nurses in outpatient settings were unintentionally exposed to chemotherapy drugs on their skin or eyes. The study emphasizes the importance of implementing nurse safety measures and adhering to national guidelines for preventing these incidents.
A new study published in The Lancet found that platinum-based doublet chemotherapy is associated with improved survival rates for elderly patients with non-small-cell lung cancer. The treatment showed better results compared to monotherapy in patients over 70 years old, suggesting a potential shift in the current treatment strategy for...
The OPTIMAL trial found erlotinib significantly prolonged median progression-free survival compared to chemotherapy (13.1 months vs 4.6 months). Serious treatment-related side effects were also more common in patients receiving chemotherapy.
Researchers found that temporarily suppressing ovarian function with triptorelin reduced the occurrence of early menopause induced by chemotherapy among premenopausal women with breast cancer. The treatment resulted in a 17% lower rate of early menopause compared to chemotherapy alone.
The EURTAC Phase III study found that erlotinib nearly doubled progression-free survival compared to chemotherapy, with a better tolerability profile for Western patients with NSCLC and EGFR activating mutations. The response rate to erlotinib was 54.5%, significantly higher than the 10.5% response rate to chemotherapy.
Research found that high EGFR expression is a predictor of improved survival in advanced non-small cell lung cancer patients treated with cetuximab and chemotherapy. Patients with high tumor EGFR expression averaged 12 months of overall survival, compared to 9.6 months for those without high expression.
A recent study published in International Journal of Cancer found that boosting the production of a specific microRNA, miR-34a, increases sensitivity of bladder cancer cells to chemotherapy. The study suggests that miR-34a may be used as a predictor of response to chemotherapy and a target for new drugs.
Rectal cancer patients may benefit from additional chemotherapy before surgery for better outcomes. City of Hope researchers also investigated the effectiveness of palliative care in late-stage lung cancer patients, finding significant gaps in current care.
Researchers found that Tai Chi improves cognitive functioning and psychological health in women who have undergone chemotherapy. The study suggests that Tai Chi could be a valuable addition to cancer treatment for mitigating cognitive decline.
A hormone test measuring anti-Mullerian hormone (AMH) levels can predict a woman's ovarian function after chemotherapy for breast cancer. Women with low AMH levels before treatment are more likely to experience infertility due to chemotherapy-induced damage.
A study published in JAMA found that delays in starting adjuvant chemotherapy after colorectal cancer surgery are associated with poorer survival outcomes. The research suggests that clinicians should prioritize timely access to chemotherapy to improve patient outcomes.
The COIN trial found that standard chemotherapy with cetuximab does not improve progression-free survival or overall survival in patients with advanced colorectal cancer. However, taking treatment breaks without compromising survival improves quality of life for most patients.
Researchers have successfully used gene-modified stem cells to protect bone marrow cells from chemotherapy's toxic effects in patients with brain tumors. The treatment involved infusing gene-modified blood stem cells into patients, which persisted for over a year without showing any harmful effects.
A new treatment combination of a PARP inhibitor with chemotherapy offered significant benefit in patients with metastatic colon cancer who had exhausted all standard therapies. The study found that the treatment controlled cancer growth for nearly six months in 23% of patients, with two experiencing a partial response.
Researchers at Ohio State University found that adding low-dose sorafenib to chemotherapy and radiation can improve treatment efficacy while reducing harsh side effects. The triple combination was well-tolerated in an animal model.
A new genomic test has shown promise as a predictor of chemotherapy response and survival benefit in women with invasive breast cancer. The test combines multiple signatures, including estrogen receptor status, endocrine therapy response, chemotherapy resistance and sensitivity, to predict treatment outcomes.
A new predictive test developed from gene expression microarrays identified patients with a high probability of survival following chemotherapy for breast cancer. The test had a positive predictive value of 56 percent and showed significant association between predicted sensitivity to treatment and improved distant relapse-free survival.
Researchers have identified sFRP1 as a molecular marker that correlates with chemotherapy sensitivity in triple-negative breast cancers. The study found that sFRP1 expression levels in individual tumors predict response to chemotherapy, and knocking down the gene in cell culture decreased sensitivity to certain chemotherapies.
Researchers found that temsirolimus strongly blocked mTOR-mediated signals and had a cytostatic effect on all mesothelioma cells. The study suggests using mTOR inhibitors as a novel anti-mesothelioma strategy, particularly in combination with chemotherapy.
A phase III clinical trial will recruit 4,000 women with low to intermediate Oncotype DX recurrence scores to determine whether a gene expression test can spare thousands of women from unnecessary chemotherapy. The RxPONDER trial aims to identify an optimal recurrence score cutpoint for these patients.
A modified chemotherapy regimen combining reduced CHOP doses with rituximab has shown substantial response and improved survival in very elderly patients with diffuse large B-cell lymphoma. The R-miniCHOP regimen is well-tolerated, with a high overall response rate and low treatment toxicity.
Researchers found that tumors with defects in DNA repair systems are less likely to recur post-surgery, reducing the need for chemotherapy. The study suggests testing for defective DNA mismatch repair and KRAS gene mutations to guide treatment strategies.
Researchers at York University have identified a key role for microRNA 376c in allowing ovarian cancer cells to thrive despite chemotherapy. By targeting the receptor ALK7, this microRNA enables cancer cells to survive and resist cell death.
A new analysis found that fish oil supplementation can help combat cancer-related malnutrition, allowing patients to maintain their weight and muscle mass during chemotherapy. The study suggests that fish oil's omega-3 fatty acids may interfere with pathways altered in advanced cancer.
A new phase III trial has shown that erlotinib has comparable efficacy to chemotherapy in non-small cell lung cancer patients whose disease has progressed after first-line treatment. The study found no difference in overall survival or progression-free survival time between the two groups.
Scientists at Queen's University Belfast have discovered the role of an enzyme that causes life-threatening damage to the heart when cancer patients receive chemotherapy, restricting treatment doses. New drugs targeting this enzyme could reduce heart damage and increase survival rates.